Management of herpes zoster and post-herpetic neuralgia now and in the future

Journal of Clinical Virology

Volumn 48, Issue SUPPL 1, 2010, Pages

  Whitley, Richard J ^a   Volpi, Antonio ^b   McKendrick, Mike ^c   Wijck, Albert van ^d   Oaklander, Anne Louise ^e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Antivirals; Management; VZV; Zoster

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACETYLSALICYLIC ACID; ACICLOVIR; AMITRIPTYLINE; ANTIVIRUS AGENT; ASP 2151; BOTULINUM TOXIN A; CAPSAICIN; CF 1743; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; DESIPRAMINE; FAMCICLOVIR; FLUOROURACIL; GABAPENTIN; GANCICLOVIR; GUANOSINE DERIVATIVE; LIDOCAINE; MORPHINE; NORTRIPTYLINE; OPIATE; OXYCODONE; PENCICLOVIR; PLACEBO; PREDNISOLONE; PREGABALIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VALOMACICLOVIR; VARICELLA ZOSTER VACCINE;

ABDOMINAL PAIN; ANALGESIA; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BURNING SENSATION; CARCINOGENICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CRYSTALLURIA; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ECG ABNORMALITY; HEADACHE; HEART ARRHYTHMIA; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; NAUSEA; NEPHROTOXICITY; NEUROMODULATION; ORTHOSTATIC HYPOTENSION; PARESTHESIA; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; URTICARIA; VARICELLA ZOSTER VIRUS; VOMITING;

ANALGESICS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; NEURALGIA, POSTHERPETIC; TREATMENT OUTCOME;

EID: 77952559533     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(10)70005-6     Document Type: Article

References (87)

1. Gnann Jr. J.W., and Whitley R.J. Clinical practice. Herpes zoster. N Engl J Med 347 (2002) 340-346
2. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al., Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352 (2005) 2271-2284
3. Scott F.T., Johnson R.W., Leedham-Green M., Davies E., Edmunds W.J., and Breuer J. The burden of herpes zoster: a prospective population based study. Vaccine 24 (2006) 1308-1314
4. Volpi A., Gatti A., Serafini G., Costa B., Suligoi B., Pica F., et al. Clinical and psychosocial correlates of acute pain in herpes zoster. J Clin Virol 38 (2007) 275-279
5. ZOVIRAX® (acyclovir) tablets [prescribing information]. GSK; November 2007.
6. VALTREX® (valacyclovir hydrochloride) [prescribing information]. GSK; September 2007.
7. Famvir® (famciclovir) tablets [prescribing information]. Novartis; December 2008.
8. Premovir® tablets [summary of product characteristics]. Berlin Chemie; May 2006.
9. Whitley R.J., and Gnann Jr. J.W. Acyclovir: a decade later. N Engl J Med 327 (1992) 782-789
10. Wood M.J. How should we measure pain in herpes zoster?. Neurology 45 Suppl 8 (1995) S61-S62
11. Arani R.B., Soong S.-J., Weiss H.L., Wood M.J., Fiddian P.A., Gnann J.W., et al. Phase specific analysis of herpes zoster associated pain data: a new statistical approach. Stat Med 20 (2001) 2429-2439
12. Wood M.J., Kay R., Dworkin R.H., Soong S.J., and Whitley R.J. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 22 (1996) 341-347
13. Beutner K.R., Friedman D.J., Forszpaniak C., Andersen P.L., and Wood M.J. Valacyclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 39 (1995) 1546-1553
14. Tyring S., Barbarash R.A., Nahlik J.E., Cunningham A., Marley J., Heng M., et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 123 (1995) 89-96
15. Shafran S.D., Tyring S.K., Ashton R., Decroix J., Forszpaniak C., Wade A., et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 29 (2004) 248-253
16. Tyring S., Barbarash R.A., Nahlik J.E., Cunningham A., Marley J., Heng M., et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 123 (1995) 89-96
17. Degreef H., and Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: results of the first controlled study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 4 (1994) 241-246
18. Tyring S.K., Beutner K.R., Tucker B.A., Anderson W.C., and Crooks R.J. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 9 (2000) 863-869
19. Volpi A., Gross G., Hercogova J., and Johnson R.W. Current management of herpes zoster: the European view. Am J Clin Dermatol 6 (2005) 317-325
20. De Clercq E. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem Pharmacol 68 (2004) 2301-2315
21. Keam S.J., Chapman T.M., and Figgitt D.P. Brivudin (bromovinyl deoxyuridine). Drugs 64 (2004) 2091-2097
22. Wassilew S.W., Wutzler P., and Brivudin Herpes Zoster Study Group. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res 59 (2003) 49-56
23. Wassilew S., and Collaborative Brivudin PHN Study Group. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol 19 (2005) 47-55
24. Okuda H., Ogura K., Kato A., Takubo H., and Watabe T. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther 287 (1998) 791-799
25. Whitley R.J. A 70-year-old woman with shingles: review of herpes zoster. JAMA 302 (2009) 73-80
26. Wood M.J., Shukla S., Fiddian A.P., and Crooks R.J. Treatment of acute herpes zoster: effect of early (<48 h) versus late (48-72 h) therapy with acyclovir and valacyclovir on prolonged pain. J Infect Dis 178 Suppl 1 (1998) S81-S84
27. Bean B., Braun C., and Balfour Jr. H.H. Acyclovir therapy for acute herpes zoster. Lancet 2 8290 (1982) 118-121
28. Wood M.J., Johnson R.W., McKendrick M.W., Taylor J., Mandal B.K., and Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 330 (1994) 896-900
29. Balfour Jr. H.H., Edelman C.K., Anderson R.S., Reed N.V., Slivken R.M., Marmor L.H., et al. Controlled trial of acyclovir for chickenpox evaluating time of initiation and duration of therapy and viral resistance. Pediatr Infect Dis J 20 (2001) 919-926
30. Johnson R, Patrick D, editors. Improving the Management of Varicella Herpes Zoster and Zoster-associated Pain. Recommendations from the IHMF Management Strategies Workshop. Management Strategies in Herpes Series. Worthing: PAREXEL MMS; 2001.
31. Severson E.A., Baratz K.H., Hodge D.O., and Burke J.P. Herpes zoster ophthalmicus in Olmsted county, Minnesota: have systemic antivirals made a difference?. Arch Ophthalmol 121 (2003) 386-390
32. Whitley R.J., Weiss H., Gnann Jr. J.W., Tyring S., Mertz G.J., Pappas P.G., et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 125 (1996) 376-383
33. Hostetler K.Y. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 82 (2009) A84-A98
34. Beadle J.R., Hartline C., Aldern K.A., Rodriguez N., Harden E., Kern E.R., and Hostetler K.Y. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents and Chemother 46 (2002) 2381-2386
35. Cidofovir [package insert]. Foster City, CA: Gilead; September 2000.
36. Epiphany Biosciences. Epiphany Announces Positive Results from its Phase 2b trial in shingles (18 November 2009). Available at: http://www.epiphanybio.com/news/2009/Press_Release_18NOV09.pdf (accessed January 2010)
37. Astellas Pharma Inc. A study with ASP2151 in subjects with recurrent episodes of genital herpes. Clinical Trial identifier: NCT00486200. Available at: http://clinicaltrials.gov/ct2/show/NCT00486200 (accessed December 2009)
38. Astellas Pharma Inc. Dose-finding study of ASP2151 in subjects with herpes zoster. Clinical Trial identifier: NCT00487682. Available at: http://clinicaltrials.gov/show/NCT00487682 (accessed December 2009)
39. McGuigan C., Yarnold C.J., Jones G., Velázquez S., Barucki H., Brancale A., et al. Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base. J Med Chem 42 (1999) 4479-4484
40. McGuigan C., and Balzarini J. FV100 as a new approach for the possible treatment of varicella-zoster virus infection. J Antimicrob Chemother 64 (2009) 671-673
41. Sienaert R., Andrei G., Snoeck R., De Clercq E., McGuigan C., and Balzarini J. Inactivity of the bicyclic pyrimidine nucleoside analogues against simian varicella virus (SVV) does not correlate with their substrate activity for SVV-encoded thymidine kinase. Biochem Biophys Res Commun 315 (2004) 877-883
42. Gershon A.A., Gershon M.D., Breuer J., Levin M.J., Oaklander A.L., and Griffiths P.D. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 48 Suppl 1 (2010) S2-S7
43. Opstelten W., McElhaney J., Weinberger B., Oaklander A.L., and Johnson R.W. The impact of varicella zoster virus: Chronic pain. J Clin Virol 48 Suppl 1 (2010) S8-13
44. Morton P., and Thomson A.N. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 102 (1989) 93-95
45. McKendrick M.W., McGill J.I., and Wood M.J. Lack of effect of acyclovir on postherpetic neuralgia. BMJ 298 (1989) 431
46. Jackson J.L., Gibbons R., Meyer G., and Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. Arch Intern Med 157 (1997) 909-912
47. Li Q., Chen N., Yang J., Zhou M., Zhou D., Zhang Q., et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2 (2009) CD006866
48. Luzio Paparatti U., Arpinelli F., and Visonà G. Herpes zoster and its complications in Italy: an observational survey. J Infect 38 (1999) 116-120
49. Volpi A., Gatti A., Pica F., Bellino S., Marsella L.T., and Sabato A.F. Clinical and psychosocial correlates of post-herpetic neuralgia. J Med Virol 80 (2008) 1646-1652
50. Strangfeld A., Listing J., Herzer P., Liebhaber A., Rockwitz K., Richter C., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 301 (2009) 737-744
51. Whitley R.J., and Gnann Jr. J.W. Herpes zoster in the age of focused immunosuppressive therapy. JAMA 301 (2009) 774-775
52. Dworkin R.H., and Schmader K.E. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 36 (2003) 877-882
53. Raja S.N., Haythornthwaite J.A., Pappagallo M., Clark M.R., Travison T.G., Sabeen S., et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 59 7 (2002) 1015-1021
54. Finnerup N.B., Otto M., McQuay H.J., Jensen T.S., and Sindrup S.H. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118 (2005) 289-305
55. Kost R.G., and Straus S.E. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Engl J Med 335 (1996) 32-42
56. Dworkin R.H. Prevention of postherpetic neuralgia. Lancet 353 9165 (1999) 1636-1637
57. Bowsher D. Acute herpes zoster and postherpetic neuralgia: effects of acyclovir and outcome of treatment with amitriptyline. Br J Gen Pract 42 (1992) 244-246
58. Watson C.P., Vernich L., Chipman M., and Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 51 (1998) 1166-1171
59. Rowbotham M., Harden N., Stacey B., Bernstein P., and Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280 (1998) 1837-1842
60. Rice A.S., and Maton S. Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 94 (2001) 215-224
61. Backonja M., and Glanzman R.L. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 25 (2003) 81-104
62. McKeage K., and Keam S.J. Pregabalin: in the treatment of postherpetic neuralgia. Drugs Aging 26 (2009) 883-892
63. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45 Suppl 6 (2004) 13-18
64. Stacey B.R., and Swift J.N. Pregabalin for neuropathic pain based on recent clinical trials. Curr Pain Headache Rep 10 (2006) 179-184
65. Greenway F.L., Frome B.M., Engels III T.M., and McLellan A. Temporary relief of postherpetic neuralgia pain with topical geranium oil. Am J Med 115 (2003) 586-587
66. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., and Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 6653 (1997) 816-824
67. Hempenstall K., Nurmikko T.J., Johnson R.W., A'Hern R.P., and Rice A.S. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med (2005) e164
68. Backonja M., Wallace M.S., Blonsky E.R., Cutler B.J., Malan Jr. P., Rauck R., et al., NGX-4010 C116 Study Group. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 7 (2008) 1106-1112
69. Rowbotham M.C., Davies P.S., Verkempinck C., and Galer B.S. Lidocaine patch: doubleblind controlled study of a new treatment method for post-herpetic neuralgia. Pain 65 (1996) 39-44
70. van Wijck A.J., Opstelten W., Moons K.G., van Essen G.A., Stolker R.J., Kalkman C.J., et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet 367 9506 (2006) 219-224
71. Kotani N., Kushikata T., Hashimoto H., Kimura F., Muraoka M., Yodono M., et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med 343 (2000) 1514-1519
72. Kim Y.H., Lee C.J., Lee S.C., Huh J., Nahm F.S., Kim H.Z., et al. Effect of pulsed radiofrequency for postherpetic neuralgia. Acta Anaesthesiol Scand 52 (2008) 1140-1143
73. Green A.L., Nandi D., Armstrong G., Carter H., and Aziz T. Post-herpetic trigeminal neuralgia treated with deep brain stimulation. J Clin Neurosci 10 (2003) 512-514
74. Lima M.C., and Fregni F. Motor cortex stimulation for chronic pain: systematic review and meta-analysis of the literature. Neurology 70 (2008) 2329-2337
75. Whitton T.L., Johnson R.W., and Lovell A.T. Use of the Rydel-Seiffer graduated tuning fork in the assessment of vibration threshold in postherpetic neuralgia patients and healthy controls. Eur J Pain 9 (2005) 167-171
76. Oaklander A.L., Romans K., Horasek S., Stocks A., Hauer P., and Meyer R.A. Unilateral postherpetic neuralgia is associated with bilateral sensory neuron damage. Ann Neurol 44 (1998) 789-795
77. Oaklander A.L. The density of remaining nerve endings in human skin with and without postherpetic neuralgia after shingles. Pain 92 (2001) 139-145
78. Simone D.A., Nolano M., Johnson T., Wendelschafer-Crabb G., and Kennedy W.R. Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function. J Neurosci 18 (1998) 8947-8959
79. Sabel B.A. Editorial: Residual vision and plasticity after visual system damage. Restor Neurol Neurosci 15 (1999) 73-79
80. Lee J.W., Siegel S.M., and Oaklander A.L. Effects of distal nerve injuries on dorsal-horn neurons and glia: relationships between lesion size and mechanical hyperalgesia. Neuroscience 158 (2009) 904-914
81. Loeser J.D., Ward Jr. A.A., and White Jr. L.E. Chronic deafferentation of human spinal cord neurons. J Neurosurg 29 (1968) 48-50
82. Loeser J.D., and Ward Jr. A.A. Some effects of deafferentation on neurons of the cat spinal cord. Arch Neurol 17 (1967) 629-636
83. Anderson L.S., Black R.G., Abraham J., and Ward Jr. A.A. Neuronal hyperactivity in experimental trigeminal deafferentation. J Neurosurg 35 (1971) 444-452
84. Basbaum A.I., and Wall P.D. Chronic changes in the response of cells in adult cat dorsal horn following partial deafferentation: the appearance of responding cells in a previously non-responsive region. Brain Res 116 (1976) 181-204
85. Sweet W.H. Deafferentation pain after posterior rhizotomy, trauma to a limb, and herpes zoster. Neurosurgery 15 (1984) 928-932
86. Lenz F.A., Tasker R.R., Dostrovsky J.O., Kwan H.C., Gorecki J., Hirayama T., et al. Abnormal single-unit activity recorded in the somatosensory thalamus of a quadriplegic patient with central pain. Pain 31 (1987) 225-236
87. Watson C.P., Deck J.H., Morshead C., Van der Kooy D., and Evans R.J. Post-herpetic neuralgia: further post-mortem studies of cases with and without pain. Pain 44 (1991) 105-117